These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
Pubmed for Handhelds
PUBMED FOR HANDHELDS
Journal Abstract Search
790 related items for PubMed ID: 22150560
1. Oncogenic alterations in papillary thyroid cancers of young patients. Sassolas G, Hafdi-Nejjari Z, Ferraro A, Decaussin-Petrucci M, Rousset B, Borson-Chazot F, Borbone E, Berger N, Fusco A. Thyroid; 2012 Jan; 22(1):17-26. PubMed ID: 22150560 [Abstract] [Full Text] [Related]
2. Concomitant BRAF(V600E) mutation and RET/PTC rearrangement is a frequent occurrence in papillary thyroid carcinoma. Guerra A, Zeppa P, Bifulco M, Vitale M. Thyroid; 2014 Feb; 24(2):254-9. PubMed ID: 23806056 [Abstract] [Full Text] [Related]
3. Diffuse sclerosing variant of papillary thyroid carcinoma: major genetic alterations and prognostic implications. Joung JY, Kim TH, Jeong DJ, Park SM, Cho YY, Jang HW, Jung YY, Oh YL, Yim HS, Kim YL, Chung JH, Ki CS, Kim SW. Histopathology; 2016 Jul; 69(1):45-53. PubMed ID: 26568156 [Abstract] [Full Text] [Related]
4. Molecular Profiling of Papillary Thyroid Carcinoma in Korea with a High Prevalence of BRAFV600E Mutation. Lee SE, Hwang TS, Choi YL, Kim WY, Han HS, Lim SD, Kim WS, Yoo YB, Kim SK. Thyroid; 2017 Jun; 27(6):802-810. PubMed ID: 28293988 [Abstract] [Full Text] [Related]
5. BRAF V600E and decreased NIS and TPO expression are associated with aggressiveness of a subgroup of papillary thyroid microcarcinoma. Bastos AU, Oler G, Nozima BH, Moysés RA, Cerutti JM. Eur J Endocrinol; 2015 Oct; 173(4):525-40. PubMed ID: 26338373 [Abstract] [Full Text] [Related]
6. NTRK fusion oncogenes in pediatric papillary thyroid carcinoma in northeast United States. Prasad ML, Vyas M, Horne MJ, Virk RK, Morotti R, Liu Z, Tallini G, Nikiforova MN, Christison-Lagay ER, Udelsman R, Dinauer CA, Nikiforov YE. Cancer; 2016 Apr 01; 122(7):1097-107. PubMed ID: 26784937 [Abstract] [Full Text] [Related]
7. BRAF mutation associated with other genetic events identifies a subset of aggressive papillary thyroid carcinoma. Costa AM, Herrero A, Fresno MF, Heymann J, Alvarez JA, Cameselle-Teijeiro J, García-Rostán G. Clin Endocrinol (Oxf); 2008 Apr 01; 68(4):618-34. PubMed ID: 18070147 [Abstract] [Full Text] [Related]
8. Genetic alterations of differentiated thyroid carcinoma in iodine-rich and iodine-deficient countries. Vuong HG, Kondo T, Oishi N, Nakazawa T, Mochizuki K, Inoue T, Tahara I, Kasai K, Hirokawa M, Tran TM, Katoh R. Cancer Med; 2016 Aug 01; 5(8):1883-9. PubMed ID: 27264674 [Abstract] [Full Text] [Related]
9. Fusion Oncogenes Are the Main Genetic Events Found in Sporadic Papillary Thyroid Carcinomas from Children. Cordioli MI, Moraes L, Bastos AU, Besson P, Alves MT, Delcelo R, Monte O, Longui C, Cury AN, Cerutti JM. Thyroid; 2017 Feb 01; 27(2):182-188. PubMed ID: 27849443 [Abstract] [Full Text] [Related]
10. RET, NTRK, ALK, BRAF, and MET Fusions in a Large Cohort of Pediatric Papillary Thyroid Carcinomas. Pekova B, Sykorova V, Dvorakova S, Vaclavikova E, Moravcova J, Katra R, Astl J, Vlcek P, Kodetova D, Vcelak J, Bendlova B. Thyroid; 2020 Dec 01; 30(12):1771-1780. PubMed ID: 32495721 [Abstract] [Full Text] [Related]
11. [BRAFV599E mutation and RET/PTC rearrangements in papillary thyroid carcinoma]. Zhu XL, Zhou XY, Zhu XZ. Zhonghua Bing Li Xue Za Zhi; 2005 May 01; 34(5):270-4. PubMed ID: 16181547 [Abstract] [Full Text] [Related]
12. Concomitant RAS, RET/PTC, or BRAF mutations in advanced stage of papillary thyroid carcinoma. Zou M, Baitei EY, Alzahrani AS, BinHumaid FS, Alkhafaji D, Al-Rijjal RA, Meyer BF, Shi Y. Thyroid; 2014 Aug 01; 24(8):1256-66. PubMed ID: 24798740 [Abstract] [Full Text] [Related]
13. BRAF mediates RET/PTC-induced mitogen-activated protein kinase activation in thyroid cells: functional support for requirement of the RET/PTC-RAS-BRAF pathway in papillary thyroid carcinogenesis. Mitsutake N, Miyagishi M, Mitsutake S, Akeno N, Mesa C, Knauf JA, Zhang L, Taira K, Fagin JA. Endocrinology; 2006 Feb 01; 147(2):1014-9. PubMed ID: 16254036 [Abstract] [Full Text] [Related]
14. High prevalence of BRAF gene mutation in papillary thyroid carcinomas and thyroid tumor cell lines. Xu X, Quiros RM, Gattuso P, Ain KB, Prinz RA. Cancer Res; 2003 Aug 01; 63(15):4561-7. PubMed ID: 12907632 [Abstract] [Full Text] [Related]
15. AGK-BRAF gene fusion is a recurrent event in sporadic pediatric thyroid carcinoma. Cordioli MI, Moraes L, Carvalheira G, Sisdelli L, Alves MT, Delcelo R, Monte O, Longui CA, Cury AN, Cerutti JM. Cancer Med; 2016 Jul 01; 5(7):1535-41. PubMed ID: 27037835 [Abstract] [Full Text] [Related]
16. Genetic Alterations and Their Clinical Implications in High-Recurrence Risk Papillary Thyroid Cancer. Lee MY, Ku BM, Kim HS, Lee JY, Lim SH, Sun JM, Lee SH, Park K, Oh YL, Hong M, Jeong HS, Son YI, Baek CH, Ahn MJ. Cancer Res Treat; 2017 Oct 01; 49(4):906-914. PubMed ID: 28052655 [Abstract] [Full Text] [Related]
17. The role of BRAF V600E mutation as a potential marker for prognostic stratification of papillary thyroid carcinoma: a long-term follow-up study. Daliri M, Abbaszadegan MR, Bahar MM, Arabi A, Yadollahi M, Ghafari A, Taghehchian N, Zakavi SR. Endocr Res; 2014 Oct 01; 39(4):189-93. PubMed ID: 24679337 [Abstract] [Full Text] [Related]